Stock listing

OTC:TRVN Trevena, Inc. Stock

Follow Trevena, Inc. into a list and get an email when it puts out news.

Share price · OTC:TRVN

$0.0005 USD 0.0000 (0.0%)

Close on Nov 16, 2026

Past year 0.0% · daily closes, Oct 16, 2026 – Nov 16, 2026, adjusted for splits
Day range
$0.0005 – $0.0005 USDNov 16, 2026
Market cap
$432 USDAt the close on Nov 16, 2026 · price × 863,788 shares outstanding
Traded on an average day
$0 USDMedian day 0 shares · 18 days with no trades · last 3 months, Oct 16, 2026 – Nov 16, 2026
Trevena, Inc. logo

Daily closes

Last 3 months, Oct 16, 2026 – Nov 16, 2026 · OTC:TRVN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00050.00000.0%$0.0005$0.0005$0.00050
$0.0005+0.0001+25.0%$0.0005$0.0005$0.0005977
$0.00040.00000.0%$0.0004$0.0004$0.00040
$0.00040.00000.0%$0.0004$0.0004$0.00040
$0.0004-0.0107-96.4%$0.0004$0.0004$0.0004117
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.01110.00000.0%$0.0111$0.0111$0.01110
$0.0111+0.0106+2120.0%$0.0111$0.0111$0.0111254
$0.00050.00000.0%$0.0005$0.0005$0.00050
$0.00050.00000.0%$0.0005$0.0005$0.00050
$0.00050.00000.0%$0.0005$0.0005$0.00050
$0.00050.00000.0%$0.0005$0.0005$0.00050
$0.00050.00000.0%$0.0005$0.0005$0.00050
$0.0005——$0.0004$0.0005$0.00044,129

Splits

2 splits since 2022 · OTC:TRVN · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-25Consolidation
Ticker
OTC:TRVN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Trevena, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Calls
9 calls with a replay · 9 with a transcript · latest Nov 14, 2023
Decks
25 decks · latest March 2025

Valuation

price Nov 16, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.23

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Trevena, Inc. · OTC:TRVNUS$432n/an/an/an/an/an/an/a0.23
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Fifty 1 Labs Inc. · OTC:FITYUS$118,532US$282,021n/a6,000×n/an/an/an/a-1.17
GB Sciences, Inc. · OTC:GBLXUS$81,414US$2.07Mn/an/an/an/an/an/a-0.46
Lyra Therapeutics, Inc. · OTC:LYRAUS$53,246US$14.42Mn/a36.2×n/an/an/an/a0.67
ZyVersa Therapeutics, Inc. · OTC:ZVSAUS$810US$1.20Bn/an/an/an/an/an/a-0.56
Median of the othersUS$164,053US$159,19018.5×0.1×−382.1%1.3×1.14

Team and board

Officers

OfficerRole
Carrie L. BourdowPresident and Chief Executive Officer
Scott ApplebaumCorporate Secretary
Robert YoderSenior Vice President and Chief Business Officer
Michael R. DoughertyExecutive Chairman

Board

DirectorRole
Leon O. MoulderChairman of the Board
Michael R. DoughertyExecutive Chairman
Anne M. PhillipsMember of Nominating and Corporate Governance Committee
Barbara YanniChair of Compensation Committee
Carrie L. BourdowPresident and Chief Executive Officer
Jake R. NunnMember of the Nominating and Corporate Governance Committee
Julie H. McHughChair of the Nominating and Corporate Governance Committee
Maxine GowenDirector
Scott BraunsteinOperating Partner at Aisling Capital Management LP

Events

Calls

CallWhenStatus
Trevena (OTC:TRVN) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q1 2023 Earnings CallMon, May 15, 2023 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q4 2022 Earnings CallThu, Mar 30, 2023 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q3 2022 Earnings CallWed, Nov 09, 2022 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q1 2022 Earnings CallWed, May 11, 2022 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q4 2021 Earnings CallThu, Mar 31, 2022 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q3 2021 Earnings CallMon, Nov 15, 2021 · 8:00 AM ETReplay
Trevena (OTC:TRVN) Q4 2020 Earnings CallTue, Mar 09, 2021 · 8:00 AM ETReplay

Results days

QuarterResults
Q3 2024Nov 7, 2024 · Before open
Q2 2024Aug 8, 2024 · Before open
Q1 2024May 15, 2024 · Before open
Q4 2023Mar 28, 2024 · Before open
Q3 2023Nov 14, 2023 · Before open
Q2 2023Aug 14, 2023 · Before open
Q1 2023May 15, 2023 · Before open
Q4 2022Mar 30, 2023 · Before open
Q3 2022Nov 9, 2022 · Before open
Q2 2022Aug 11, 2022 · Before open
All 16 quarters
QuarterResults
Q1 2022May 11, 2022 · Before open
Q4 2021Mar 31, 2022 · Before open
Q3 2021Nov 15, 2021 · Before open
Q2 2021Aug 12, 2021 · Before open
Q1 2021May 6, 2021 · Before open
Q4 2020Mar 9, 2021 · Before open

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck36 slidesMarch 2025
Investor Presentation (April 2024)Investor deck32 slidesApr 1, 2024
Investor Presentation (January 2024)Investor deck31 slidesJanuary 2024
Corporate Update (November 2023)Corporate update34 slidesNov 14, 2023
Investor Presentation (October 2023)Investor deck30 slidesOctober 2023
Investor Presentation (September 2023)Investor deck31 slidesSep 6, 2023
Investor Presentation (September 2023)Investor deck31 slidesSeptember 2023
Investor Presentation (May 2023)Investor deck39 slidesMay 15, 2023
Investor Presentation (March 2023)Investor deck55 slidesMar 30, 2023
Investor Presentation (January 2023)Investor deck52 slidesJan 9, 2023
All 25 decks
DeckKindSlidesDate
Investor Presentation (January 2023)Investor deck22 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck51 slidesNov 9, 2022
Investor Presentation (July 2022)Investor deck46 slidesJul 28, 2022
Investor Presentation (April 2022)Investor deck52 slidesApr 20, 2022
Corporate Update (March 2022)Corporate update51 slidesMar 31, 2022
Investor Presentation (June 2021)Investor deck50 slidesJun 16, 2021
Investor Presentation (May 2021)Investor deck50 slidesMay 6, 2021
Investor Presentation (April 2021)Investor deck50 slidesApr 21, 2021
Investor Presentation (March 2021)Investor deck49 slidesMar 9, 2021
Investor Presentation (November 2020)Investor deck41 slidesNov 2, 2020
Q2 2020 Earnings PresentationEarnings41 slidesAug 10, 2020
Investor Presentation (June 2020)Investor deck41 slidesJun 2, 2020
Investor Presentation (May 2020)Investor deck40 slidesMay 18, 2020
Investor Presentation (April 2019)Investor deck43 slidesApril 2019
Corporate Update (May 2016)Corporate update16 slidesMay 2, 2016

Open Decks

Financials

Annual, in USD

Income statement

LineFY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue3.13M-418.0K567.0K3.07M31.0K5.73M03.75M6.25M0
Cost of revenue1.67M3.02M954.0K182.0K108.0K0490.0K90.0M44.1M40.5M
Gross profit1.46M-3.44M-387.0K2.89M-77.0K5.73M-490.0K3.75M6.25M-40.5M
Research and development16.3M18.2M13.4M13.1M13.3M15.8M49.0M90.0M44.1M40.5M
Selling, general and administrative21.5M34.7M38.1M19.2M13.2M19.0M19.6M16.1M12.8M9.40M
Operating income-35.3M-56.4M-51.9M-29.5M-26.6M-30.5M-70.4M-102.3M-50.6M-49.9M
Depreciation and amortization334.0K382.0K428.0K477.0K562.0K645.0K490.0K246.0K207.9K239.4K
EBITDA-35.0M-56.0M-51.5M-29.0M-26.0M-29.9M-69.9M-102.0M-50.4M-49.7M
Interest expense3.64M1.26M1.00K29.0K931.0K2.23M2.78M1.74M334.4K70.7K
Income before tax-40.0M-53.7M-51.6M-29.1M-24.9M-30.0M-71.9M-103.0M-50.5M-49.7M
Income tax318.0K-2.71K-428.0K300.0K3.19M745.0K3.39M-246.0K-207.9K254.7K
Net income-40.3M-53.7M-51.2M-29.4M-24.9M-30.8M-71.9M-103.0M-50.5M-49.7M
Earnings per share, basic-2.84-7.59-7.84-5.75-6.78-10.46-30.23-49.14-28.84-50.40

Balance sheet

LineFY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash and equivalents33.0M38.3M66.9M109.4M32.3M32.9M16.6M24.3M46.8M36.2M
Short-term investments3.50M28.6M49.5M86.3M125.9M70.7M
Receivables171.0K0
Inventory0906.0K2.35M10000
Current assets35.2M41.0M70.7M119.0M37.5M62.1M67.5M112.4M174.5M107.6M
Property, plant and equipment5.71M6.55M2.25M2.71M3.39M3.81M1.06M696.3K553.3K
Goodwill0000
Total assets40.6M48.7M80.1M127.7M47.0M66.8M72.7M114.7M175.4M108.3M
Accounts payable2.30M2.37M4.55M1.69M1.05M1.42M1.42M8.75M6.75M4.34M
Current liabilities7.55M8.73M9.19M16.6M9.11M17.5M18.2M22.0M13.6M6.96M
Long-term debt30.8M13.4M4.81M15.7M13.3M18.2M1.79M
Total debt36.2M19.8M7.10M7.80M13.5M17.4M28.2M18.3M36.4M3.51M
Total liabilities48.3M33.1M15.5M23.7M16.9M25.3M38.1M36.1M32.2M9.13M
Shareholders' equity-7.66M15.6M64.6M104.1M30.1M41.5M34.6M78.6M143.1M99.2M
Shares outstanding14.2M7.07M6.53M5.10M3.67M2.94M2.38M2.10M1.75M986.2K

Cash flow

LineFY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations-33.0M-51.5M-50.2M-21.4M-23.7M-25.4M-71.3M-91.6M-40.1M-39.8M
Capital spending-41.0K-28.0K-16.0K-27.0K-27.0K-169.0K-3.50M-605.0K-376.2K-440.4K
Free cash flow-33.1M-51.5M-50.2M-21.4M-23.7M-25.5M-74.8M-92.2M-40.5M-40.2M
Cash from investing-41.0K18.0K-16.0K3.47M25.6M21.0M32.8M37.8M-56.9M-71.2M
Cash from financing26.3M23.5M7.73M95.0M-2.50M20.6M31.0M32.3M107.6M109.2M
Dividends paid-37.0K-393.0K-1.07M-158.0K0000
Share buybacks-2.00K-37.0K-393.0K-1.07M-158.0K33.3M21.1M32.3M91.2M107.4M
Change in cash-6.76M-28.0M-42.5M77.1M-581.0K16.2M-7.49M-21.4M10.6M-1.76M

Open Financials

Cap table

Built by 6ix from Trevena, Inc.’s releases

Common shares
863,788
Fully diluted
863,788

Fully diluted

LineShares
Common shares863,788

Share count over time

CountShares
Nov 22, 2026863,788

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Terrance McGuire
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Jan 30, 2014 – May 14, 2014 · Past
François Nader
Other companies: Tectonic Therapeutic, Inc. (Chair, Board of Directors · Since at least Feb 23, 2026); Moderna, Inc. (Director · Since at least Dec 10, 2019); Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Alexion Pharmaceuticals Inc (Director · Nov 15, 2017 – Jul 21, 2021 · Past); Baxalta Inc (Director · Jul 27, 2015 – Jun 3, 2016 · Past); Acceleron Pharma Inc (Director · Dec 11, 2014 – Nov 19, 2021 · Past); NPS Pharmaceuticals Inc (President, CEO and Director, Director · Apr 8, 2013 – Feb 21, 2015 · Past)
Director · Jan 30, 2014 – May 20, 2015 · Past
Maxine Gowen
Other companies: Passage Bio, Inc. (Chairwoman · Since at least Feb 18, 2021); Aclaris Therapeutics, Inc. (Director · Since at least Jul 2, 2019); Aceragen Inc. (Director · Jan 4, 2015 – Aug 10, 2023 · Past); Akebia Therapeutics, Inc. (Director · Jul 28, 2014 – Jun 5, 2020 · Past); Human Genome Sciences Inc (Director · Feb 15, 2008 – Jul 30, 2012 · Past)
Director · Since at least Jan 30, 2014
Anne Phillips
Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Aug 1, 2024); vTv Therapeutics Inc. (Director · Since at least Mar 13, 2024); Vaccitech plc (Director · Apr 29, 2021 – May 11, 2023 · Past); AMAG Pharmaceuticals Inc (Director · Apr 10, 2019 – Nov 16, 2020 · Past)
Member of Nominating and Corporate Governance Committee · Since at least Dec 16, 2014
Farah Champsi
Other companies: Population Health Investment Co Inc (Director · Nov 17, 2020 – Jan 26, 2021 · Past); Kite Pharma Inc (Director · Jun 19, 2014 – Oct 3, 2017 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 28, 2013 · Past); Chimerix Inc (Director · Apr 10, 2013 – Oct 23, 2013 · Past)
Director · Jan 30, 2014 – Dec 10, 2014 · Past
Julie McHugh
Other companies: Lantheus Holdings, Inc. (Director · Since at least Jan 25, 2017); Ironwood Pharmaceuticals, Inc. (Chair, Biopharmaceutical Industry Executive, Retired · Since at least Jun 1, 2016); Evelo Biosciences, Inc. (Director · Apr 9, 2021 – Jun 8, 2023 · Past); Aerie Pharmaceuticals Inc. (Director · Jun 8, 2016 – Nov 21, 2022 · Past)
Chair of the Nominating and Corporate Governance Committee · Since at least May 18, 2016
Leon O Moulder Jr
Other companies: Zenas BioPharma, Inc. (See Remarks, Director · Since at least Sep 12, 2024); Zai Lab Ltd. (Director · Since at least Jan 1, 2021); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – May 23, 2024 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past)
Director · May 16, 2018 – Jun 15, 2023 · Past
Jason Raleigh Nunn
Other companies: Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Regulus Therapeutics Inc (Director · Since at least Jun 6, 2019)
Director · May 16, 2019 – Jun 13, 2024 · Past
David F Solomon
Other companies: Clinical Data Inc (Vice President, Director · Apr 13, 2011 – Apr 13, 2011 · Past); Forest Laboratories Inc (SVP-CorpDev/Strategic Planning · Dec 8, 2008 – Dec 6, 2013 · Past)
Director · Jan 30, 2014 – May 14, 2014 · Past
John P. Hamill
Other companies: Aprea Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Jan 30, 2023); Windtree Therapeutics, Inc. (SVP & CFO · Jul 20, 2020 – Jul 26, 2022 · Past)
VP Fin,Princ Fin&Acct Officer · May 31, 2019 – May 31, 2019 · Past
All 25 people
PersonSeat
Barry Shin
Other companies: Compass Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 9, 2024)
Acting COO and CFO · Jun 25, 2019 – Oct 8, 2024 · Past
John M Limongelli
Other companies: Neos Therapeutics Inc (SVP & General Counsel · Mar 20, 2019 – Mar 19, 2021 · Past)
Sr. VP,General Counsel & CAO · Feb 28, 2018 – Feb 28, 2018 · Past
Marvin Johnson
Other companies: Marinus Pharmaceuticals Inc (Director · Apr 17, 2023 – Feb 7, 2025 · Past)
Director · Mar 18, 2021 – Jun 13, 2024 · Past
Barbara YanniChair of Compensation Committee · Since at least Nov 5, 2026
Carrie L. BourdowPresident and Chief Executive Officer · Since at least Nov 5, 2026
Jake R. NunnMember of the Nominating and Corporate Governance Committee · Since at least Nov 5, 2026
Katrine SuttonVP, Finance · Nov 26, 2024 – Nov 26, 2024 · Past
Leon O. MoulderChairman of the Board · Since at least Nov 5, 2026
Mark DemitrackActing CMO · Dec 2, 2023 – Oct 8, 2024 · Past
Michael R. DoughertyExecutive Chairman · Since at least Nov 5, 2026
Patricia M DrakeSVP, Chief Commercial Officer · Nov 10, 2022 – Dec 14, 2023 · Past
Robert PracharSr. VP, Corp. Strategy · Mar 31, 2014 – Mar 31, 2014 · Past
Robert YoderSenior Vice President and Chief Business Officer · Since at least Nov 5, 2026
Scott ApplebaumCorporate Secretary · Since at least Nov 5, 2026
Scott BraunsteinOperating Partner at Aisling Capital Management LP · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Trevena, Inc.